Fortress Biotech 9.375% Series A Preferred Stock
FBIOP
3 hedge funds and large institutions have $7.29M invested in Fortress Biotech 9.375% Series A Preferred Stock in 2021 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 2 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0.24% less ownership
Funds ownership: 8.43% → 8.19% (-0.24%)
3% less capital invested
Capital invested by funds: $7.51M → $7.29M (-$219K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
-$122K |
| 2 |
SAM
Shikiar Asset Management
New York
|
-$90.4K |
FBIOP Hedge Fund Activity: Q3 2021 in Review
3 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) for Q3 2021, worth a combined $7.29M — down 2.9% from $7.51M a quarter earlier.
Fund positioning in FBIOP was balanced in Q3 2021: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.
The largest seller was Uniplan Investment Counsel, cutting an estimated $122K.
- 3 institutional investors held Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $7.29M of Fortress Biotech 9.375% Series A Preferred Stock stock for Q3 2021, down 2.9% quarter-over-quarter.
- 0 funds opened new Fortress Biotech 9.375% Series A Preferred Stock positions in Q3 2021 and 0 closed out.
- The largest Fortress Biotech 9.375% Series A Preferred Stock seller in Q3 2021 was Uniplan Investment Counsel, an estimated $122K sold.
Based on aggregated 13F filings for Q3 2021.